Medicare GLP-1 Bridge Program: New $50 Copay Path for Ozempic and Wegovy — Who Qualifies

# Medicare GLP-1 Bridge Program: New $50 Copay Path for Ozempic and Wegovy — Who Qualifies

> **Quick answer:** The Medicare GLP-1 Bridge Program launches July 1, 2026, offering Wegovy and Zepbound (not Ozempic) at a $50 monthly copay to eligible Part D beneficiaries. You need a BMI of 35 or higher — or 27 or higher with a qualifying condition like hypertension or heart disease — and your doctor must complete a prior authorization before July 1. Critical catch: if you receive the Medicare Extra Help (LIS) subsidy, those benefits do not apply here. You will pay $50 regardless of your income — a significant equity gap in the program's design.

*This article is for informational purposes only and does not constitute financial or medical advice. Consult a licensed insurance counselor (SHIP), your Medicare plan, and a qualified healthcare provider for guidance specific to your situation.*

The Medicare GLP-1 Bridge Program is the most significant change to Medicare drug coverage for seniors in years — and the most misunderstood. Headlines say "Medicare now covers Ozempic." That's not accurate. The reality is more specific, more useful, and more complicated. Here is exactly what the program covers, who gets in, what it costs at the insurance level, and where the coverage equity gap quietly sits.

## What CMS Actually Built — and Why It Works Outside Part D

The Medicare GLP-1 Bridge is a demonstration program operated by the Centers for Medicare and Medicaid Services (CMS). It runs from **July 1, 2026 through December 31, 2027**. The design is unusual: rather than running through your existing Part D plan, the Bridge uses a **central processor** — a separate CMS-contracted system — that handles prior authorization approvals and pharmacy reimbursements directly.